Full Press Release Details
| Dr. Reddy's Laboratories Ltd. | |
| 8-2-337, Road No. 3, Banjara Hills, | |
| Hyderabad - 500 034, Telangana, | |
| India. | |
| CIN : L85195TG1984PLC004507 | |
| Tel :+91 40 4900 2900 | |
| Fax :+91 40 4900 2999 | |
| Email : mail@drreddys.com | |
| www.drreddys.com |
| Corporate Relationship Department | National Stock Exchange of India Ltd. |
| BSE Limited | " Exchange Plaza" |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
| Mumbai - 400 001 | Mumbai - 400 051 |
| Fax Nos.: | 022-22723121 / 22723719 / | Fax Nos.: | 022-26598120/ 26598237/ |
| 22722037 / 22722039 | 26598238 |
Please find enclosed a Press Release on
"Dr. Reddy's Laboratories Limited to present at the 36th Annual J.P. Morgan Healthcare Conference".
This is for your information and record.
| With regards, | |
| /s/ Sandeep Poddar | |
| Sandeep Poddar | |
| Company Secretary |
CC:- New York Stock Exchange Inc.(Stock Code :RDY)
| CONTACT | ||
| DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS |
| 8-2-337, Road No. 3, Banjara Hills, | Saunak SAVLA | Calvin Printer |
| Hyderabad - 500034. Telangana, India. | saunaks@drreddys.com | calvinprinter@drreddys.com |
| (Ph: +91-40-49002135) | (Ph: +91-40- 49002121) |
Reddy's Laboratories Limited to present at the
J.P. Morgan Healthcare Conference
Hyderabad, India and Princeton, NJ, USA. January 6, 2018 -
Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced that the Company will be presenting at the
36th Annual J.P. Morgan Healthcare Conference in San Francisco, California.
Alok Sonig, Executive Vice President and Head, North America
will present on Tuesday, January 9, 2018 at 2 p.m. (PST) [3:30 a.m. IST on January 10, 2018].
Presentation material will be available on the Company's
website www.drreddys.com
Biographical Information:
Alok Sonig is Executive Vice President (Global) and Head of
the North America region for Dr. Reddy's Laboratories. He is a member of the Global Management Council for the corporation.
Alok joined Dr. Reddy's in June 2012, running both the India-region in addition to Global Business Development. During his
tenure, the India business delivered industry-leading growth and saw successful acquisitions and integration of strategically important
businesses. Prior to joining Dr. Reddy's, Sonig spent nearly 15 years at Bristol-Myers Squibb, where he held several leadership
positions in general management, country leadership, global strategy and marketing, mostly based in the U.S. His last role was
Vice President of Strategy in Princeton, New Jersey. Before joining Bristol-Myers Squibb, Sonig was based in Washington, D.C.,
where he spent several years as a management consultant working in various industries on strategy and innovation assignments, including
health care, technology and telecommunications. Currently, he is a board member of the Association for Accessible Medicine. He
holds a Bachelors of Engineering degree from Punjab Engineering College in India, as well as a Masters in Business Administration
from American University in Washington, D.C. Sonig is married with two daughters and lives in the Princeton, New Jersey, area.
About Dr. Reddy's: Dr. Reddy's Laboratories
Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics
and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical
services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular,
diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets
include - USA, Russia & CIS and India. For more information, log on to: www.drreddys.com
Disclaimer: This press release may include
statements of future expectations and other forward-looking statements that are based on the management's current views and
assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ
materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of
context, the words "may", "will", "should", "expects", "plans", "intends",
"anticipates", "believes", "estimates", "predicts", "potential", or "continue"
and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those
in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit
defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality
and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and
regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including
related integration issues.
The company assumes no obligation to update any information